Repligen (RGEN)
(Real Time Quote from BATS)
$120.81 USD
-0.01 (-0.01%)
Updated Jul 10, 2024 03:18 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Brokerage Reports
Repligen Corporation [RGEN]
Reports for Purchase
Showing records 41 - 60 ( 207 total )
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
1Q23 Solid; 5% Lower FY23; Positive View on LT Growth
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Interphex - Activity, Tone and Technology Present Compelling Future for Bioprocessing
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
FlexBiosys Acquisition Positioning Repligen for 2024 Top-Line Acceleration
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Obesity/Diabetes Therapeutics, Far Surpassing Estimates
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
2023 Life Sciences & MedTech Investor Forum: Key Takeaways
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Risk Factors for Life Science May Be de Minimis
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
4Q22 Earnings Beat and FY23 Guidance Initial Thoughts
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
4Q22 Beats and FY23 Guide Shows Investment in LT Outlook
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
JPM Takeaways, Positive Industry Backdrop for 2023
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department